Ultragenyx Pharmaceutical Inc. RARE
Set alert
16.30 USD +0.20 +1.24%
At close · Nov 2
16.30 0.00 0.00%
After hours · Nov 2, 4:00 PM ET
15.85 Day range 16.44
12.73 52-week range 39.89
- YTD
- -29.13%
- 1 year
- -52.89%
- Open
- 16.29
- Prev close
- 16.10
- Mkt cap
- 1.61B
- Vol
- 4.84M
- Avg vol
- 4.21M
- EPS
- -5.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.85
- High
- 16.44
- Forward P/E
- 72.25
- Beta
- 0.36
- Short ratio
- 3.79
- Inst. own
- 120.04%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 17.01
- 200-d avg
- 22.90
- 1y target
- 26.25
Analyst view
Consensus: buy
Buy
Price target (mean) 26.25 +61.0% upside
Now 16.30
- Target (low)
- 16.00
- Target (mean)
- 26.25
- Target (high)
- 39.00
Ratings (0m) 21 10 buy · 11 hold · 0 sell
- Strong buy2
- Buy8
- Hold11
- Sell0
- Strong sell0
Recommendation trend
- This month 21
- 1 month ago 20
- 2 months ago 20
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.75132 | -1.25 – 0.75 | -1.81 | +58.5% | 183.71M | +14.9% | 6 |
| Next quarter | -0.66246 | -1.08 – 0.78 | -1.29 | +48.7% | 229.66M | +10.9% | 6 |
| Current year | -4.08 | -4.96 – -1.18 | -5.83 | +30.1% | 760.21M | +13.0% | 6 |
| Next year | 0.22559 | -1.69 – 4.50 | -4.08 | +105.5% | 997.05M | +31.1% | 6 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | UBS | Initiated | — | Neutral |
| Sep 21, 2026 | Evercore ISI Group | Maintained | In-Line | In-Line |
| Sep 21, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 18, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Sep 18, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 18, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 18, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Sep 17, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 4, 2026 | Goldman Sachs | Maintained | Neutral | Neutral |
| Sep 4, 2026 | Barclays | Maintained | Overweight | Overweight |
| Sep 3, 2026 | JP Morgan | Downgrade | Overweight | Neutral |
| Sep 3, 2026 | Jefferies | Maintained | Buy | Buy |
| Sep 3, 2026 | William Blair | Downgrade | Outperform | Market Perform |
| Sep 3, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 3, 2026 | TD Cowen | Maintained | Buy | Buy |
| Sep 3, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Sep 3, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 3, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Sep 3, 2026 | Evercore ISI Group | Downgrade | Outperform | In-Line |
| Sep 3, 2026 | Baird | Downgrade | Outperform | Neutral |
| Sep 3, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 3, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 28, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 25, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 21, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Aug 20, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 20, 2026 | Citigroup | Maintained | Buy | Buy |
| Aug 20, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 20, 2026 | Cantor Fitzgerald | Maintained | Overweight | Overweight |
| Aug 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |